Biliary Atresia Treatment Market, by Disease Type (Type I, Type II, and Type III), by Treatment Type (Medications (Bile Acids, Antibiotics, and Corticosteroids) and Surgery), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

Published In : Nov 2021

Code : CMI4779

Pages :191

Formats :

Excel and PDF

Industry : Pharmaceutical

Biliary Atresia Treatment MarketSize and Trends

The global biliary atresia treatment market is estimated to be valued at US$ 910.7 million in 2021 and is expected to exhibit a CAGR of 7.7% during the forecast period (2021-2028).

The increasing prevalence of biliary atresia and its surgery is expected to drive the market growth during the forecast period.

The increasing incidence of biliary atresia and its surgery is expected to drive the market growth during the forecast period. For instance, according to an article published by Research Gate in March 2016, babies born with biliary atresia during 1997 to 2010 were identified from the Taiwan National Health Insurance Research Database. Moreover, among 513 total biliary atresia cases, about 457 (89%) cases underwent the surgery (Kasai procedure).

Increasing advancements in laboratory screening and diagnosis of biliary atresia is expected to drive the market growth during the forecast period.

The increasing advancements in laboratory screening and diagnosis of biliary atresia by researchers and key players are expected to drive the biliary atresia treatment market growth during the forecast period. For instance, according to an article published in the journal ‘Digestive Medical Research’ in September 2021, recent advancements in non-invasive molecular markers, such as gamma-glutamyl transpeptidase (GGT), matrix metalloproteinase-7 (MMP7), interleukin-33 (IL-33), and stool proteomics showed promising results as effective diagnostic markers in biliary atresia.